Best practice principles for cholesterol lowering

Nigel Capps, Marc Evans*, Terry McCormack, Jan Procter-King, Gershan Davis, Stewart Findlay, Clive Weston, Jonathan Morrell

*Corresponding author for this work

Research output: Contribution to journalArticle (journal)peer-review


In 2006, 78% of patients with coronary heart disease (CHD) achieved the National Quality and Outcomes Framework (QOF) of the General Medical Services (GMS) target of 5.0 mmol/L for total cholesterol. This is a significant achievement in secondary prevention and shows that the standard of care in the UK is becoming aligned with that of the rest of Europe. Nevertheless, the UK still has one of the highest CHD mortality rates in Europe, and we need therefore to continue to work towards improving the quality of care and achieving more clinically meaningful targets for high-risk patients. The current targets outlined by the GMS for lipid lowering are less stringent than the newer evidence-based recommended targets of <4.0 mmol/L for total cholesterol and <2.0 mmol/L for low-density lipoprotein cholesterol (LDL-C) suggested by the recent Joint British Societies' Guidelines on Prevention of Cardiovascular Disease in Clinical Practice (JBS2). This supplement outlines a new treatment algorithm for suggested best practice for cholesterol lowering, incorporating the latest strategies and thinking.

Original languageEnglish
Pages (from-to)1-16
Number of pages16
JournalBritish Journal of Cardiology
Issue number1
Publication statusPublished - 31 May 2007


  • anion exchange resin
  • antilipemic agent
  • atorvastatin
  • docosahexaenoic acid
  • ezetimibe
  • ezetimibe plus simvastatin
  • fibric acid derivative
  • flora pro activ
  • gemfibrozil
  • high density lipoprotein cholesterol
  • hydroxymethylglutaryl coenzyme A reductase inhibitor
  • hypocholesterolemic agent
  • icosapentaenoic acid
  • low density lipoprotein cholesterol
  • nicotinic acid
  • omega 3 fatty acid
  • rosuvastatin
  • simvastatin
  • sitostanol
  • stanol ester
  • unclassified drug
  • cardiovascular disease
  • cholesterol blood level
  • clinical trial
  • control strategy
  • cost effectiveness analysis
  • drug absorption
  • drug dose titration
  • drug megadose
  • Europe
  • evidence based practice
  • health care organization
  • health care quality
  • high risk patient
  • hypercholesterolemia
  • hypertriglyceridemia
  • ischemic heart disease
  • low drug dose
  • medical service
  • mortality
  • practice guideline
  • rotein synthesis inhibition


Dive into the research topics of 'Best practice principles for cholesterol lowering'. Together they form a unique fingerprint.

Cite this